| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 937451 | Neuroscience & Biobehavioral Reviews | 2013 | 5 Pages |
•Cognitive impairment contributes heavily to poor functional outcome in schizophrenia.•Research in animal models holds promise for discovery of new treatments to improve cognition.•Construct validity of animal cognitive testing paradigms is critical for predicting efficacy of treatments.•This special issue summarizes CNTRICS selections of animal paradigms for assessing novel treatments for cognition in schizophrenia.
Over the past two decades, the awareness of the disabling and treatment-refractory effects of impaired cognition in schizophrenia has increased dramatically. In response to this still unmet need in the treatment of schizophrenia, the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative was developed. The goal of CNTRICS is to harness cognitive neuroscience to develop a brain-based set of tools for measuring cognition in schizophrenia and to test new treatments. CNTRICS meetings focused on development of tasks with cognitive construct validity for use in both human and animal model studies. This special issue presents papers discussing the cognitive testing paradigms selected by CNTRICS for animal model systems. These paradigms are designed to measure cognitive constructs within the domains of perception, attention, executive function, working memory, object/relational long-term memory, and social/affective processes.
